EP1740221A4 - Methods and compositions for the treatment of polycystic diseases - Google Patents

Methods and compositions for the treatment of polycystic diseases

Info

Publication number
EP1740221A4
EP1740221A4 EP05804799A EP05804799A EP1740221A4 EP 1740221 A4 EP1740221 A4 EP 1740221A4 EP 05804799 A EP05804799 A EP 05804799A EP 05804799 A EP05804799 A EP 05804799A EP 1740221 A4 EP1740221 A4 EP 1740221A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
polycystic diseases
polycystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05804799A
Other languages
German (de)
French (fr)
Other versions
EP1740221A2 (en
Inventor
Oxana Beskrovnaya
Herve Husson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1740221A2 publication Critical patent/EP1740221A2/en
Publication of EP1740221A4 publication Critical patent/EP1740221A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP05804799A 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases Withdrawn EP1740221A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56667004P 2004-04-29 2004-04-29
US59038504P 2004-07-22 2004-07-22
PCT/US2005/014982 WO2005117941A2 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Publications (2)

Publication Number Publication Date
EP1740221A2 EP1740221A2 (en) 2007-01-10
EP1740221A4 true EP1740221A4 (en) 2009-01-07

Family

ID=35463346

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05804799A Withdrawn EP1740221A4 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Country Status (6)

Country Link
EP (1) EP1740221A4 (en)
JP (1) JP2007535562A (en)
BR (1) BRPI0510367A (en)
CA (1) CA2564092A1 (en)
MX (1) MXPA06012446A (en)
WO (1) WO2005117941A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1957539T1 (en) 2005-12-08 2013-05-31 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
EP1808694A1 (en) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2617423A1 (en) * 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN103429270B (en) 2008-08-25 2016-11-23 埃克斯雷德制药有限公司 Stop antisense nucleotide of Connective Tissue Growth Factor and application thereof
CA2825059A1 (en) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
JP5995207B2 (en) * 2014-11-28 2016-09-21 学校法人 学習院 Boron-containing porphyrin derivatives
KR102288447B1 (en) * 2018-12-28 2021-08-10 서울대학교산학협력단 Composition for diagnosing polycystic kidney disease comprising agent for detecting CTGF and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043335A1 (en) * 1997-12-25 2000-10-11 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2003024308A2 (en) * 2001-09-18 2003-03-27 Fibrogen, Inc. Methods of assaying connective tissue growth factor
WO2003053340A2 (en) * 2001-12-10 2003-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043335A1 (en) * 1997-12-25 2000-10-11 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2003024308A2 (en) * 2001-09-18 2003-03-27 Fibrogen, Inc. Methods of assaying connective tissue growth factor
WO2003053340A2 (en) * 2001-12-10 2003-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DELL K M ET AL: "A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, LONDON, GB, vol. 60, no. 4, 1 October 2001 (2001-10-01), pages 1240 - 1248, XP002223746, ISSN: 0085-2538 *
HUSSON H ET AL: "Combination of SAGE and custom microarray technologies for expression profiling of normal and ADPKD epithelia", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 13, no. Program and Abstracts Issue, 4 October 2002 (2002-10-04), pages 117A, XP008098855, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
CA2564092A1 (en) 2005-12-15
WO2005117941A3 (en) 2006-05-18
MXPA06012446A (en) 2007-01-17
WO2005117941A2 (en) 2005-12-15
JP2007535562A (en) 2007-12-06
BRPI0510367A (en) 2007-11-06
EP1740221A2 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
EP1737482A4 (en) Compositions and methods for treating diseases
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200704677B (en) Compositions and methods for the treatment of autism
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP1893216A4 (en) Methods and compositions for the treatment of ocular disorders
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
IL178860A (en) Certain chemical entities and compositions for the treatment of proliferative diseases
EP1644021A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
EP1786265A4 (en) Novel compositions and methods of treatment
EP1711197A4 (en) Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1796675A4 (en) Compositions and methods for treating ophthalmic diseases
ZA200804500B (en) Methods and compositions for the treatment of gastro-intestinal disorders
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
EP1720563A4 (en) Methods and compositions for the treatment of inflammation
EP1765331A4 (en) Methods and compositions for the treatment of pulmonary diseases
EP1858524A4 (en) Compositions and methods for treatment of autoimmune and related diseases
IL187405A0 (en) Methods and compositions for the treatment of pain
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
SI1812797T1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1781318A4 (en) Methods and compositions for the treatment of polycystic diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061020

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081209

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20081203BHEP

Ipc: A61K 39/395 20060101AFI20081203BHEP

Ipc: A61P 13/12 20060101ALI20081203BHEP

Ipc: C07K 16/22 20060101ALI20081203BHEP

17Q First examination report despatched

Effective date: 20091012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100423